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Changes in nutritional status associated with
unresectable pancreatic cancer
SJ Wigmore, CE Plester, RA Richardson and KCH Fearon
University Department of Surgery, Royal Infirmary, Lauriston Place, Edinburgh EH3 9YW, UK
Summary Weight loss is common in patients with pancreatic cancer; however, the nature and progress of their nutritional depletion are not
well documented. In this study, pre-illness weight and duration of weight loss were recorded in 20 patients with histologically confirmed
unresectable cancer of the pancreas. Patients then underwent nutritional analysis at monthly intervals until death. The median period of
assessment was 27 weeks (interquartile range 22.5-38.0 weeks). At the time of diagnosis, all patients had lost weight [median 14.2%
(10.0-20.0%) of pre-illness stable weight], and this weight loss was progressive, increasing to a median of 24.5% by the time of the last
assessment (P =0.0004). Body mass index was significantly reduced from a pre-illness median value of 24.9 kg m-2 (22.4-27.4 kg m-2) to
20.7 kg m-2 (19.5-23.6 kg m-2) at the time of diagnosis and further to 17.7 kg m-2 (16.6-23.1 kg m-2) just before death (P =0.0003). Further
evidence of tissue depletion was evident from the significant reductions in lean body mass [43.4 kg (36.9-53.0 kg) to 40.1 kg (33.5-50.7 kg)
P =0.008] and fat mass [12.5 kg (8.9-17.8 kg) to 9.6 kg (6.3-15.1 kg) P =0.03). This study confirms that the majority of patients with
unresectable pancreatic cancer have already undergone significant weight loss by the time of diagnosis and that the natural history of this
process is one of inexorable progression. These results highlight the need for selective non-toxic therapeutic intervention to attenuate
cachexia and indicate that such interventions should be instituted early in the course of the disease.
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Pancreatic cancer is the fifth most common cause of cancer death
in the Western world. At the time of diagnosis, tumour resection
with curative intent is only possible in 10-15% of subjects, leaving
a large population with poor prognosis and limited therapeutic
options (Carter, 1995). The care of such patients has focused on
relief of symptoms, such as pain, jaundice, steatorrhoea, nausea
and anaemia in an attempt to optimize quality of life.
One of the most distressing features of pancreatic cancer is
marked and progressive weight loss (Falconer et al, 1995). Patients
often report a decreased dietary intake, which may be caused by a
combination of factors, such as anorexia, early satiety, anxiety,
depression, pain and nausea. Patients who develop gastric outlet
obstruction suffer from severe vomiting, which may require
surgery, and this is almost inevitably accompanied by significant
weight loss. Some patients have significant malabsorption and
require pancreatic replacement therapy; others develop diabetes,
which may be difficult to control. In addition, we have recently
demonstrated that patients with pancreatic cancer have an elevated
resting metabolic rate compared with age- and sex-matched
controls (Falconer et al, 1994). This phenomenon may contribute
further to the negative energy balance observed in such patients.
Nutritional depletion is associated with reduced resistance to
infection, muscle weakness and impaired healing (Bistrain et al,
1975; Haydock and Hill, 1986; Jeejebhoy, 1986). Moreover,
progressive weight loss has been associated with profound effects
on psychological state (Larsson et al, 1995).
When considering therapeutic intervention, it is vital to have
documented the natural history of the disease. In this study,
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20 patients with histologically proven unresectable cancer of the
pancreas underwent nutritional assessment at the time of their diag-
nosis and monthly thereafter until they were unable to attend follow-
up (within 2 months of death). Weight has limitations as a marker of
nutritional depletion and, in order to identify the nature and extent of
tissue loss in patients with cachexia, it is important to define changes
in body composition (Hill, 1988). Therefore, in addition to measure-
ment of body weight, upper arm anthropometry and bioelectrical
impedance analysis were performed. To our knowledge, a longitu-
dinal study of weight loss and the nature of nutritional depletion in a
homogeneous group of untreated patients with unresectable pancre-
atic cancer has not been reported previously.
PATIENTS AND METHODS
Subjects
Twenty patients with unresectable adenocarcinoma of the pancreas
confirmed by histology were studied. The group comprised 12
men and 8 women of median age 60 years. None of the patients
received either cytotoxic chemotherapy, radiotherapy or active
nutritional intervention, but were given full supportive care.
Before the study, relief of biliary or gastric outlet obstruction had
been effected in nine patients by palliative bypass surgery and in
ten by endoscopic insertion of a biliary stent. The following
assessments were performed.
At the initial visit, pre-illness stable weight and duration of
weight loss were documented. Recall weight loss was validated
where possible by examination of patients' records of unrelated
previous attendance at hospital. Height was measured using a
wall-mounted stadiometer, with the patients standing erect and
without shoes. At each visit, patients were weighed on spring
balance scales (Seca, Germany). Mid-upper arm circumference
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(MUAC) was measured at the midpoint between the acromion and
olecranon process. Triceps skinfold thickness (TSF) was measured
using Harpenden calipers and mid-arm muscle circumference
(MAMC) was calculated using Jelliffe's equation. Actual values
were expressed as a percentage of Jelliffe's standards to provide an
approximation of nutritional depletion (Jelliffe, 1966). At each
visit, patients underwent clinical examination and the presence of
either ascites or peripheral oedema was recorded.
Body composition analysis
Bioelectrical impedance analysis was performed using a four-
terminal impedance analyser (BIA-101, RJL Systems, USA).
Electrodes were positioned on the right hand and foot, and the
measurement was made with patients in a supine position and with
limbs slightly abducted from the body. Resistance (R) at 50 kHz
was recorded. Total body water (TBW) was calculated from equa-
tions previously derived following measurement of TBW (by dilu-
tion of tritiated water) on a heterogeneous surgical patient
population, which included a large proportion of cancer patients
(Fearon et al, 1992). Lean body mass (LBM) and fat mass (FM)
were calculated from TBW using established formulae (Elia, 1992).
C-reactive protein and plasma albumin assays
Serum concentration of the acute phase reactant C-reactive protein
was measured using an immunoturbimetric assay (Abbott TDX,
Abbott Laboratories, Maidenhead, UK). Serum albumin was
measured using an automated bromocresol green dye binding
technique.
Statistical analysis
Results are expressed as median and interquartile range.
Comparison of data at different time points was performed using
the Wilcoxon sign rank test.
RESULTS
Patient characteristics
Changes in weight and body mass index
The median recalled pre-illness stable weight was 63.7 kg
(52.4-84.0 kg) giving a pre-illness BMI similar to the range of
values for the general adult population: 24.9 (22.4-27.4). At the
time of diagnosis the majority of patients had lost weight [17/20
(85%)] and before death all of the patients had lost weight (Table
1). The median weight of patients at the time of diagnosis was 53.2
kg (47.9-71.1 kg), which represented 14.2% (10.0-20.0%) of pre-
illness stable weight, and this weight loss was accompanied by a
significant reduction of median BMI to 20.7 kg m-2 (19.5-23.6 kg
m-2) (P=0.002 vs pre-illness BMI). During the course of the study,
further weight loss occurred, such that before death patients had
lost 24.5% of their pre-illness stable weight (P=0.0004)(Figure 1),
and their median BMI had decreased further to 17.7 kg m-2
(16.6-23.1 kg m-2) (P=0.0003). The median amount of weight lost
by the time of diagnosis was 9 kg (5.5-12.5 kg), and between diag-
nosis and just before death patients lost a further 5 kg (3.6-7.9 kg),
a total decrease of 14 kg. If a percentage weight loss >20% is
assumed to indicate severe malnutrition (Windsor and Hill,
1988a), 3 out of 20 (15%) patients would be classified as severely
malnourished at diagnosis, whereas before death 12 out of 20
(60%) would be included in this category. Similarly, at diagnosis 7
out of 20 (35%) patients had a BMI <20 kg m-2 and would be clas-
sified as underweight (Garrow, 1988), whereas just before death
the majority of patients (13/20 i.e. 65%) had a BMI of <20 kg m-2.
Arm muscle circumference
At the time of diagnosis, the median AMC was 21.9 cm
(19.9-24.6 cm), representing a value of 91.5% (84.5-99.5%) of the
mean value for the general adult population. Just before death, the
median AMC had reduced significantly to 18.9 cm (16.6-21.8 cm),
representing 77% (70.5-90.0%) of the mean value for the general
adult population (P=0.0003). The median decline in AMC between
diagnosis and death was 2.1 cm (1.2-5.2 cm). If it is assumed that
an AMC <85% of the mean value for the general adult population
indicates malnutrition, the percentage of patients who would be
The median age of patients was 60 years (range 42-83 years); 12
were male and 8 female. No patient had evidence of peripheral
oedema or ascites at the time of diagnosis. By the time of the last
visit, three patients had clinical evidence of peripheral oedema and
two had ascites.
Table 1 Weight, percentage weight loss and upper arm anthropometry at
diagnosis and just before death (n=20)
At diagnosis Before death P-value
Weight (kg) 53.2 (47.9-71.1) 49.4 (41.9-61.9) 0.0004
BMI 20.7 (19.5-23.6) 17.7 (16.6-23.1) 0.0003
PIWL 14.2 (10-20) 24.5 (11.5-29.7) 0.0004
TSF (mm) 10.0 (7.2-13.3) 5.7 (4.5-9.5) 0.0002
AMC (cm) 21.9 (19.9-24.6) 18.9 (16.6-21.8) 0.0003
Median and interquartile range, values at diagnosis vs death compared using
a Wilcoxon sign rank test.
5-
0-
Weight loss as - 5-
percentage of
pre-illness stable - lo-
weight
-1i5-
-20-
-25-
I;
-3-2-1 0 1 2 3 4 5 6
Time (months)
Figure 1 Weight loss as a percentage of pre-illness stable weight in 20
patients with unresectable pancreatic cancer. Percentage weight loss
between onset of weight loss and the time of diagnosis (time 0 months) is
indicated by the broken line. Subsequent percentage weight loss based on
clinical measurements is indicated by the solid boxes and lines. Vertical bars
indicate interquartile ranges
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Table 2 Body composition, albumin and C-reactive protein at diagnosis and
before death (n=20)
At diagnosis Before death P-value
LBM (kg) 43.4 (36.9-53.3) 40.1 (33.5-50.7) 0.008
Fat mass (kg) 12.5 (8.9-17.8) 9.6 (6.3-15.1) 0.03
TBW (I) 31.7 (26.9-38.9) 29.3 (24.5-37.0) 0.008
C-reactive protein 10 (10-50) 35 (7-66) 0.02
(mg 1_')
Serum albumin 42 (38-46) 34.5 (29-37) 0.0007
Median and interquartile range, values at diagnosis vs death compared using
a Wilcoxon sign rank test.
classified as malnourished increases from 30% at the time of diag-
nosis to 70% just before death (Gray and Gray, 1979).
Triceps skinfold thickness
At the time of diagnosis, the median TSF was 10.0 mm (7.2-
13.3 mm), representing a value of70% (53-84%) of the mean value
for the general adult population. Just before death, the median TSF
had dropped significantly to 5.7 mm (4.5-9.5 mm), representing
43% (31-70%) of the mean value for the general adult population
(P=0.0002). The median decrease in TSF between diagnosis and
death was 2.1 mm (0.9-4.9 mm). A TSF of <80% of the mean value
for the general adult population is commonly taken to indicate
malnutrition (Gray and Gray, 1979). In this study, the percentage of
patients who would be classified as malnourished increased from
65% at the time of diagnosis to 90% just before death.
Body composition at diagnosis and near to death
Biolectrical impedance analysis demonstrated a significant decline
in both FM and LBM between the time of diagnosis and death
(Table 2). The median loss ofLBM was 2.9 kg (1.6-7.2 kg) and of
FM 2.7 kg (0.9-4.4 kg). At diagnosis, no patients had clinical
evidence of peripheral oedema or ascites. The median TBW
content in this group was 31.71 (26.9-38.9 1), representing 55.3%
of body weight and in the middle of the normal range for the
general adult population, i.e. 50-60% of body weight. Before
death, the TBW had decreased to 29.3 1 (24.5-37.0 1) (P=0.008),
presumably due to an overall decrease in body weight (see Table
1). As a percentage of body weight, TBW increased from 55.3%
(51.8-59.9%) to 59.1% (55.6-62.2%), however this was not statis-
tically significant. At the time of death, two patients had clinical
evidence of peripheral oedema and two had ascites.
DISCUSSION
In this study, progressive changes in nutritional status have been
investigated in a group of patients with pancreatic cancer from
before the time of diagnosis to a time point close to death. Body
weight is the most commonly used indicator of nutritional status in
the UK and is readily obtainable in the setting of an outpatient
clinic (Payne-James et al, 1992). In order to take account of height,
BMI was also calculated. This study has demonstrated that
patients with pancreatic cancer have lost approximately 15% of
their pre-illness stable weight by the time of diagnosis, and that
this weight loss continues to progress with a median weight loss of
25% of pre-illness stable weight by the time of death. Using a
weight loss >20% to signify severe malnutrition, 15% of patients
in this study would be classified as severely malnourished at diag-
nosis, while just before death this proportion had increased to
60%. Similarly, using a BMI of <20 kg m-2 to signify malnutrition,
35% of patients were malnourished at the time of diagnosis
increasing to 65% just before death.
The principal disadvantage of weight and BMI as indicators of
nutritional status are that they do not provide specific information
on the nature of tissue loss. In malnourished, hypoalbuminaemic or
metabolically stressed individuals, weight is often influenced by
oedema and, therefore, weight or BMI will tend to underestimate
nutritional depletion in such patients (Barac-Nieto et al, 1978;
Starker et al, 1985). In the present study, subcutaneous fat and
skeletal muscle were estimated by anthropometry, and body
composition was measured by bioelectrical impedance analysis.
Significant reduction of arm muscle circumference was observed
such that, at the time of diagnosis, 30% of patients had significant
arm muscle protein depletion (i.e. <85% of standardized reference
values) and by the time of death this proportion had risen to 70% of
patients. Similarly, depletion of subcutaneous fat, which represents
20-75% of total fat stores, was observed. Using a TSF <80% to
signify malnutrition, 55% of patients would be classified as signif-
icantly malnourished at diagnosis and 90% just before death. These
data confirm previous detailed studies of body composition in the
cancer patient, which have demonstrated that the principal tissues
depleted are skeletal muscle and fat (Fearon and Preston, 1990).
At diagnosis, the median TBW content was approximately 32 1,
respresenting 55% of body weight, and was within the normal
range for the general adult population (50-60%). At this time, no
patient had clinical evidence of peripheral oedema or ascites. Just
before death, the TBW content had decreased significantly to 29 1,
presumably owing to an overall decrease in body weight. As a
percentage of total weight, TBW increased from 55% to 59%;
however, this difference was not statistically significant. It is
known that starvation causes the body to retain sodium and water,
hence the chronically starved subject often shows much less
weight loss than expected (Boulter et al, 1973). The present study
suggests that patients with pancreatic cancer exhibit a state that is
characterized by hypoalbuminaemia with a trend towards a relative
expansion of total body water space. Detailed body composition
analysis in cachectic patients with lung cancer has suggested that
this phenomenon may be explained by maintenance of total body
water despite depletion of fat and muscle protein stores (Fearon
and Preston, 1990). This picture of relative (but not absolute)
expansion ofTBW combined with hypoalbuminaemia may or may
not be accompanied by clinical signs or oedema. In patients who
do not have peritoneal pancreatic carcinomatosis, clinically avail-
able signs of fluid retention, such as oedema or ascites, tend not to
be apparent until a very late stage in the natural history of the
disease; indeed, in the present study at the time of the final assess-
ment only five patients had clinical evidence of perpipheral
oedema or ascites.
Progressive nutritional depletion is a source of considerable
distress and anxiety to patients with pancreatic cancer. In addition,
it may have significant implications for their duration and quality
of life (Inagaki et al, 1974). The morbidity and mortality associ-
ated with undernutrition have been related to the loss of total body
protein, and this is reflected by the high incidence of hypostatic
pneumonia as the terminal event in the starving patient (Moore,
1980). Windsor and Hill (1988b) have shown that patients with
more than 15% weight loss are likely to have clinically significant
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(i.e. >20%) loss of total body protein, and at this level of lean
tissue depletion have shown that physiological function (e.g. respi-
ratory muscle function) is significantly impaired. By the end of the
present study, the degree of weight loss observed was such that the
majority of patients would be included in this high-risk category.
Cachexia associated with malignancy has long been a thera-
peutic target. However, few approaches have resulted in gain of
lean tissue. Studies that have targeted impaired protein-energy
intake by means of enteral or parenteral hyperalimentation have
been disappointing (Cohn et al, 1982; Bozetti, 1992). These
studies have demonstrated that, when weight is gained, it is usually
as a consequence of an increase in total body water and fat rather
than gain in skeletal muscle protein. Under these circumstances,
nutritional support is unlikely to be effective in reducing morbidity
and mortality. Kern and Norten (1988) have indicated that thera-
peutic intervention in cancer cachexia must address both the
protein-energy deficit and the underlying metabolic derange-
ments, which prevent effective use of nutrients. Recent studies
have attempted to target such metabolic derangements using
anti-inflammatory drugs, such as ibuprofen (Wigmore et al, 1995),
and immunomodulatory agents, such as eicosapentaenoic acid
(Wigmore et al., 1996). This study indicates that nutritional deple-
tion is already established by the time of diagnosis in the majority
of patients with pancreatic cancer and that, untreated, it will
continue to a point at which protein depletion is so marked that
complications of starvation and impaired muscle physiology are
likely. Therapeutic intervention should, therefore, be afforded a
higher priority in the palliative care of such patients and should be
instituted as early as possible in the natural history of the disease.
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